Long trade : CLVS +60 % (6/22)

•  6/15: #4; vol 21.0M
• 6/17: 4, 60; vol. 19.3M

This week's biggest % winners & losers : Mar 28 - Apr 1, 2022 (wk 13)

The following are this week's top percentage gainers and losers, categorized by sectors (over $300 mln market cap and 100K average daily volume).

This week's top % gainers

• Healthcare: CLVS (2.58 +61.25%), GH (72.43 +22.22%), IMGN (5.03 +17.96%), LNTH (58.24 +16.71%), NVRO (75.89 +16.09%), QURE (19.3 +15.16%), TCMD (21.38 +14.58%)
• Industrials: TISI (2.45 +48.18%), NLSN (27.3 +22.51%)
• Consumer Discretionary: SRI (21.85 +17.85%), LOVE (50.94 +15.12%)
• Financials: AMBC (10.23 +17.05%), JRVR (25.22 +15.42%)
• Energy: HMLP (7.27 +16.69%), DO (6.94 +15.67%)
• Consumer Staples: CALM (58.22 +15.8%), VGR (12.37 +14.28%)
• Utilities: SBS (10.88 +15.69%)

This week's top % losers

• Healthcare: NEO (12.26 -30.3%), EVLO (3.36 -20.57%), ARRY (10.95 -16.19%), CASI (0.72 -15.51%), CGC (7.36 -15.3%), TLRY (7.46 -12.85%)
• Industrials: ARCB (74.07 -13.98%), HUBG (69.59 -13.41%), JBHT (181.35 -13.31%), LLL (3.79 -13.27%), SAIA (229.82 -12.92%)
• Consumer Discretionary: UXIN (1.00 -31.04%), CONN (14.69 -24.19%), SNBR (50.33 -12.36%)
• Financials: BCS (7.92 -12.54%)
• Energy: KLXE (5.34 -17.59%)
• Consumer Staples: RAD (8.25 -15.44%), NBEV (0.55 -12.42%)

-=Clovis Oncology (CLVS) to seek FDA approval for ovarian cancer drug as a maintenance therapy

 

Clovis Oncology Rubraca significantly improves progression-free survival in first-line maintenance treatment in women with ovarian cancer regardless of their biomarker status in phase 3 athena-mono trial

• ATHENA study evaluating Rubraca monotherapy versus placebo (ATHENA-MONO) successfully achieved the primary endpoint of improved PFS in both populations in the primary efficacy analyses: HRD-positive and all patients randomized.
• Median PFS of 20.2 months for Rubraca vs 9.2 months for placebo in the ITT population.
• The exploratory PFS endpoints were also achieved in both HRD-negative and BRCA mutant subgroups of patients.
• Safety of Rubraca observed in ATHENA-MONO was consistent with both the current US and European labels.
• ATHENA-MONO results will serve as the basis of a supplemental NDA for US label expansion to be submitted during Q2 2022; European submission to follow during Q3 2022.
• These data, including additional analyses, have been submitted for presentation at the American Society of Clinical Oncology Annual Meeting in June 2022.

Great trade : CLVS (4/15)